There is also additional scope for primary care to be involved in pharmacotherapy initiation, especially with the advent of highly effective GLP-1 therapy for obesity (i.e., semaglutide, tizepatide) [4, 39]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.